key: cord-0763438-g6b860qc
authors: Xiong, Yuan; Zhu, Guang-Hao; Wang, Hao-Nan; Hu, Qing; Chen, Li-Li; Guan, Xiao-Qing; Li, Hui-Liang; Chen, Hong-Zhuan; Tang, Hui; Ge, Guang-Bo
title: Discovery of naturally occurring inhibitors against SARS-CoV-2 3CLpro from Ginkgo biloba leaves via large-scale screening
date: 2021-04-22
journal: Fitoterapia
DOI: 10.1016/j.fitote.2021.104909
sha: 5a69b32b707141fe12b57ec1027859e7cecc08cd
doc_id: 763438
cord_uid: g6b860qc

3-Chymotrypsin-like protease (3CLpro) is a virally encoded main proteinase that is pivotal for the viral replication across a broad spectrum of coronaviruses. This study aims to discover the naturally occurring SARS-CoV-2 3CLpro inhibitors from herbal constituents, as well as to investigate the inhibitory mechanism of the newly identified efficacious SARS-CoV-2 3CLpro inhibitors. Following screening of the inhibitory potentials of eighty herbal products against SARS-CoV-2 3CLpro, Ginkgo biloba leaves extract (GBLE) was found with the most potent SARS-CoV-2 3CLpro inhibition activity (IC50 = 6.68 μg/mL). Inhibition assays demonstrated that the ginkgolic acids (GAs) and the bioflavones isolated from GBLE displayed relatively strong SARS-CoV-2 3CLpro inhibition activities (IC50 < 10 μM). Among all tested constituents, GA C15:0, GA C17:1 and sciadopitysin displayed potent 3CLpro inhibition activities, with IC50 values of less than 2 μM. Further inhibition kinetic studies and docking simulations clearly demonstrated that two GAs and sciadopitysin strongly inhibit SARS-CoV-2 3CLpro via a reversible and mixed inhibition manner. Collectively, this study found that both GBLE and the major constituents in this herbal product exhibit strong SARS-CoV-2 3CLpro inhibition activities, which offer several promising leading compounds for developing novel anti-COVID-19 medications via targeting on 3CLpro.

The pandemic of coronavirus disease 2019 (COVID- 19) , an unprecedented disease caused by severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), is sweeping expeditiously all over the world [1, 2] . Owing to the high infectivity and lack of efficacious drugs, COVID-19 is putting unprecedented pressures to public health, economic development, and global safety [3] . As to April 12th, 2021, COVID-19 has infected over 136.5 million people and has killed more than 2.9 million people worldwide [4] . Currently, scientists around the world are trying to find efficacious therapeutics for combating COVID-19, via targeting on several validated therapeutic targets [5] . Among all identified therapeutic targets for treating COVID-19, the conserved 3-chymotrypsin-like protease (3CL pro ), a key enzyme responsible for coronavirus replication, has been validated as a pivotal therapeutic target for fighting this pandemic [6] . 3CL pro is a virally encoded main proteinase that implicated in the maturation the functional proteases by cleaving the viral polyproteins [7, 8] , dysfunction or strong inhibition on 3CL pro will block the replication of multiple coronaviruses.

The crucial role of 3CL pro in coronavirus replication has aroused great interests in discovery of efficacious 3CL pro inhibitors as the leading compounds for the development of novel antiviral agents. Although a wide range of phytochemicals and synthetic molecules have been reported with anti-3CL pro activity [9, 10] , the efficacious SARS-CoV-2 3CL pro inhibitors with high potency and favorable safety profiles are rarely reported. Thus, it is an urgent need for discovering more efficacious SARS-CoV-2 3CL pro inhibitors to develop novel antiviral agents to fight COVID-19. It is well-known that the phytochemicals from medicinal plants remain one of the major sources for discovery of the leading compounds for drug J o u r n a l P r e -p r o o f development [11] , while some natural compounds (such as flavonoids [12] , triterpenes [13] , and phenolic compounds [14] ) have been reported with 3CL pro inhibition activity, encouraging us to find more potent SARS-CoV-2 3CL pro inhibitors from herbal medicines.

For this purpose, a large-scale screening campaign was performed by us, in which a total of 80 herbal products were collected and the inhibition potentials of these herbal products against SARS-CoV-2 3CL pro were assayed via a biochemical approach. After screening, we noticed that the Ginkgo biloba leaves extract (GBLE) displayed the most potent SARS-CoV-2 3CL pro inhibition activity (IC 50 = 6.68 μg/mL), which encouraged us to further characterize the key constituents in Ginkgo biloba leaves responsible for SARS-CoV-2 3CL pro inhibition.

This study intended to assay the inhibition potentials for the major phytochemicals isolated from GBLE, as well as to explore the inhibitory mechanisms of the newly identified SARS-CoV-2 3CL pro inhibitors from this herbal product. For these purposes, a total of twenty natural products isolated from Ginkgo biloba leaves were collected, while the inhibitory potentials of these compounds against SARS-CoV-2 3CL pro were carefully assayed. Among purity of 99 %. The stock solution of this fluorescent substrate was prepared by Millipore water and stored at 4 °C. The buffer was prepared using Millipore water (Millipore, Bedford, USA) and stored at 4 °C for further use. HPLC grade DMSO (Tedia, USA) was used throughout.

A Smt3-SARS-CoV-2 3CL pro fusion construct was Escherichia coli (E. coli) codon optimized and cloned into the pET29a (+) vector [17, 18] . The 3CL pro cleavage site (SAVLQS ↓ GFRK) located at the N-terminus of SARS-CoV-2 3CL pro . The C-terminus of SARS-CoV-2 3CL pro was followed by a modified HRV 3C protease cleavage site (SGVTFQ order to check ligand-receptor interactions.

The IC 50 values and the K i values were evaluated by nonlinear regression using Graph Pad Prism 7.0 software (GraphPad Software, Inc., La Jolla, USA).

Firstly, the inhibition potentials of 80 herbal products (100 μg/mL, final concentration) on SARS-CoV-2 3CL pro were screened by using Dabcyl-KNSTLQSGLRKE-Edans as a FRET-based substrate. As depicted in Fig.1 , among all tested herbal products, GBLE displayed the most potent 3CL pro inhibition activity, and this herbal product could inhibit nearly 70% hydrolytic activity of SARS-CoV-2 3CL pro at 100 μg/mL. To further quantify the inhibitory activity of GBLE, the dose-inhibition curve of GBLE on SARS-CoV-2 3CL pro was plotted using increasing dosages (from 1.25 to 100 μg/mL). As shown in Fig.2 , GBLE dose-dependently inhibit the target enzyme, with the calculated IC 50 value of 6.68 μg/mL. This finding suggests that GBLE contains naturally occurring inhibitors against SARS-CoV-2 3CL pro .

Next, twenty known major constituents in GBLE were collected, including the bioflavones (amentoflavone, ginkgetin, bilobetin, isoginkgetin, sciadopitysin), flavones (kaempferol, quercetin, apigenin, isorhamnetin, genkwanin, luteolin, quercetrin), the terpene lactones (bilobalide, ginkgolide A, ginkgolide B, ginkgolide C), as well as GAs (C13:0, C15:0, C15:1, J o u r n a l P r e -p r o o f and C17:1) [24] . To discover SARS-CoV-2 3CL pro inhibitors in an efficient way, three inhibitor concentrations (1 μM, 10 μM and 100 μM) of each tested compound were used for screening of the SARS-CoV-2 3CL pro inhibition activity (Fig.3) . Among all tested constituents isolated from GBLE, two flavones (kaempferol, quercetrin) and the terpene lactones displayed extremely weak inhibition on SARS-CoV-2 3CL pro (IC 50 > 100 μM). By contrast, the bioflavones and the GAs exhibited relatively strong inhibitory effects on SARS-CoV-2 3CL pro (IC 50 < 10 μM). Meanwhile, five flavones (genkwanin, quercetin, isorhamnetin, luteolin, apigenin) in GBLE showed moderate inhibition on SARS-CoV-2 3CL pro , with the IC 50 values ranged from 10 μM to 100 μM. The dose-inhibition curves of these phytochemicals isolated from GBLE were depicted in Fig.4 and Fig.S5 while their IC 50 values were listed in Table 1 . It is obvious from Table 1 that the GAs and a bioflavone (sciadopitysin) display strong SARS-CoV-2 3CL pro inhibition activities, while the IC 50 values are lower than that of the positive inhibitor (ebselen).

To further investigate the inhibitory mechanisms of the newly identified 3CL pro inhibitors in GBLE, three potent SARS-CoV-2 3CL pro inhibitors (GA C15:0, GA C17:1 and sciadopitysin) isolated from GBLE were selected for inhibition kinetic studies. As shown in SARS-CoV-2 3CL pro , implying that these agents may bind on this key target enzyme at both catalytic site and another non-catalytic site.

To gain deeper insights into the inhibitory mechanisms of the GAs and sciadopitysin against SARS-CoV-2 3CL pro , a dimer crystal structure of SARS-CoV-2 3CL pro was used for docking simulations [22] . Firstly, the possible ligand-binding pockets in SARS-CoV-2 3CL pro were assessed by utilizing the ligandability and druggability scores calculated by CavityPlus.

As shown in Fig.6 and Table S1 , three druggable pockets (the V site located at the dimer interface, and two catalytic sites of both chain A and chain B) were identified as possible ligand-binding pockets of this key enzyme. Docking simulations demonstrated that GA C15:0, GA C17:1 and sciadopitysin could be well-docked into both the V site and the catalytic sites of SARS-CoV-2 3CL pro , while the predicted binding energies of three compounds binding on either the V site or the catalytic site were listed in Table S2 .

The key interactions between three newly identified 3CL pro inhibitors and SARS-CoV-2 3CL pro were also analyzed. As shown in Fig.S7 and Fig.S8 , the GAs (including C15:0 and C17:1) created strong interactions with some residuals surrounding on the V site mainly on hydrophobic interactions and hydrogen bonding. Meanwhile, these two hydrophobic compounds could also occupy the catalytic site of 3CL pro via hydrophobic interactions and hydrogen bond interactions, as well as the Pi-sulfur interaction with the key catalytic residue (Cys145). By contrast, sciadopitysin interact with the residuals surrounding on both the V site and the catalytic site mainly on hydrophobic interactions and hydrogen bonding (Fig.S9) .

Notably, the phenolic groups of sciadopitysin at both the C-19 and the C-21 sites played targeting on several validated therapeutic targets [6] . Among all identified therapeutic targets for treating COVID-19, 3CL pro is a promising therapeutic target owing to its indispensable role in the replication of this new coronavirus [25] . Until now, the efficacious 3CL pro inhibitors with high potency and favorable safety profiles are rarely reported. Thus, there is an urgent need for discovering more efficacious 3CL pro inhibitors for the development of therapeutic agents for combating COVID-19. To find naturally occurring 3CL pro inhibitors, a screening campaign was performed to discover the herbal medicine(s) with anti-SARS-CoV-2 3CL pro activity. Within all tested eighty herbal products, GBLE exhibited the most potent SARS-CoV-2 3CL pro inhibition activity, with the IC 50 value of 6.68 μg/mL. This finding encouraged us to identify the key bioactive constituents in GBLE responsible for SARS-CoV-2 3CL pro inhibition, as well as to investigate the inhibitory mechanisms of these newly identified naturally occurring 3CL pro inhibitors.

As a popular herb used in both western and eastern countries, Ginkgo biloba leaves have been widely applied for preventing and treating a variety of human diseases, including cardiovascular disorders, pulmonary disease, and central nervous system diseases [26] [27] [28] .

Increasing evidence has indicated that some major constituents (such as bioflavones and GAs) J o u r n a l P r e -p r o o f in GBLE exhibited broad antiviral activities against a wide range of DNA (such as human Cytomegalovirus) and RNA (such as SARS-CoV, Ebola virus and human immunodeficiency virus) viruses [12, [29] [30] [31] . However, the anti-SARS-CoV-2 effects of GBLE have not been reported yet. In this study, our findings revealed that both GBLE and several phytochemicals in this herbal extract (such as the bioflavones and GAs) could strongly inhibit the hydrolytic activity of 3CL pro , suggesting that GBLE and its major phytochemicals might block the replication of SARS-CoV-2 via targeting this pivotal enzyme. In addition to the anti-3CL pro activity, previous studies have revealed that GBLE constituents (such as the bioflavones) could modulate the blood coagulation and ameliorates inflammation both in vitro and in vivo [28, [32] [33] [34] . It is well-known that COVID-19 is a complex, multi-organ and heterogeneous illness, the severe disease cases are frequently accompanied by the hypercoagulable inflammatory state [35, 36] . As one of the most popular herbal medicines, Ginkgo biloba leave extract possess a variety of beneficial effects, such as anti-coagulate, anti-inflammatory, anti-oxidative lowing blood pressure, anti-obesity, and other biological activities [26, 32, [37] [38] [39] . Thus, it is easily conceivable that GBLE may bring significant benefits to the COVID-19 patients with certain underlying medical conditions (such as cardiovascular disease, stroke, high blood pressure, diabetes, and obesity), by alleviating the major symptoms of both COVID-19 and other underlying health problems.

It is well-known that the bioflavones are the major class of bioactive constitutes in GBLE.

Previous studies have reported that the bioflavones isolated from GBLE and other medicinal plants exhibited a wide range of beneficial effects, including anti-thrombin, anti-oxidative, anti-inflammatory, and antiviral activities [28, 31, 32, 40] . It also has been reported that the J o u r n a l P r e -p r o o f bioflavones displayed strong SARS-CoV 3CL pro inhibition potency [31] . This study found that the bioflavones isolated from GBLE displayed strong inhibition against SARS-CoV-2 3CL pro potency. These findings suggested that the natural bioflavones could act as promising lead compounds for developing anti-COVID-19 or the broad-spectrum anti-CoVs agents.

Nevertheless, most naturally occurring bioflavones are found with poor membrane permeability, poor solubility, and extremely poor oral bioavailability [32] . To develop more efficacious orally administrated 3CL pro inhibitors, the natural bioflavones should be extensively modified to simultaneously improve the inhibition potency and the drug-likeness properties. Another strategy is to develop the nasal administration systems for delivery of the bioactive bioflavones to lung, for blocking replication of COVID-19 virus at this target organ and then alleviating the major symptoms of COVID-19. In addition to bioflavones, GAs in GBLE were also found with strong SARS-CoV-2 3CL pro inhibition activities (IC 50 < 5 μM).

Accumulating evidence has demonstrated that GAs possess a wide range of antiviral effects via disturbing the viral replication [29, 30, 41] . Generally, the levels of toxic ginkgolic acids in marketed Ginkgo biloba products are strictly limited lowering than 5 ppm, owing to that these agents have strong toxicity and could cause severe allergic reactions [42] . In these cases, GAs is not recommended as the orally administrated agents for treating COVID-19, but these abandoned ingredients could be used as the disinfection or cleaning products for external use.

Structurally, the GAs isolated from GBLE bear a hydrophobic long chain and these compounds could be easily modified as the surfactants. In the future, new antiviral surfactants could be synthesized and developed using GAs as the starting materials, which also can be used in combination with other marketed disinfectants for the prevention and 

In summary, this study revealed the key ingredients in Ginkgo biloba leaves extract (GBLE) responsible for SARS-CoV-2 3CL pro inhibition and investigated the inhibitory effects of the newly identified SARS-CoV-2 3CL pro inhibitors isolated from GBLE. Following assessing the inhibitory potentials of twenty phytochemicals isolated from GBLE against SARS-CoV-2 3CL pro , the bioflavones and the GAs were found with efficacious SARS-CoV-2 3CL pro inhibition activities (IC 50 < 10 μM). Among all tested phytochemicals in GBLE, two GAs (GA C15:0, GA C17:1) and a bioflavone (sciadopitysin) displayed the most potent SARS-CoV-2 3CL pro inhibition activities. Inhibition kinetic analyses demonstrated these three newly identified 3CL pro inhibitors strongly inhibit SARS-CoV-2 3CL pro in a reversible and mixed-inhibition manner, with K i values of 0.73 μM, 1.02 μM and 2.96 μM, for GA C15:0, GA C17:1, and sciadopitysin respectively. Docking simulations showed that two GAs and sciadopitysin could be well-docked into two druggable pockets (the V site and the catalytic sites) of SARS-CoV-2 3CL pro , which agreed well with the mixed-inhibition modes of these 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) pandemic: A global health emergency

Impact of COVID-19 on the social, economic, environmental and energy domains: Lessons learnt from a global pandemic

Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update

SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus

3CL inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy

The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020

Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery

Roles of flavonoids against coronavirus infection

Specific Covid-19-inducing coronavirus

A new bilobalide isomer and two cis-coumaroylated flavonol glycosides from Ginkgo biloba leaves

Structure of M from SARS-CoV-2 and discovery of its inhibitors

Protein production by auto-induction in high density shaking cultures

Production of authentic SARS-CoV M pro with enhanced activity: Application as a novel tag-cleavage endopeptidase for protein overproduction

Discovering Severe Acute Respiratory Syndrome Coronavirus 3CL Protease Inhibitors: Virtual Screening, Surface Plasmon Resonance, and Fluorescence Resonance Energy Transfer Assays

Inhibition of UGT1A1 by natural and synthetic flavonoids

Inhibition of human carboxylesterases by magnolol: Kinetic analyses and mechanism

CavityPlus: a web server for protein cavity detection with pharmacophore modelling, allosteric site identification and covalent ligand binding ability prediction

Advances in the chemical constituents and chemical analysis of Ginkgo biloba leaf, extract, and phytopharmaceuticals

Essential functional molecules associated with SARS-CoV-2 infection: Potential therapeutic targets for COVID-19

The effects of Ginkgo biloba on metabolic syndrome: A review

Targeted metabolomic profiling of cardioprotective effect of Ginkgo biloba L. extract on myocardial ischemia in rats

Evaluation of the anti-inflammatory properties of the active constituents in Ginkgo biloba for the treatment of pulmonary diseases

Ginkgolic acid inhibits fusion of enveloped viruses

Ginkgolic acid inhibits HIV protease activity and HIV infection in vitro

Bioflavones from Ginkgo biloba as inhibitors of human thrombin

Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety

Protective effects of Ginkgo Biloba Dropping Pills against liver ischemia/reperfusion injury in mice

COVID-19: A collision of complement, coagulation and inflammatory pathways

COVID-19: Staging of a New Disease Comment

The dynamic association between COVID-19 and chronic disorders: An updated insight into prevalence, mechanisms and therapeutic modalities

Bioflavones from Ginkgo biloba as novel pancreatic lipase inhibitors: Inhibition potentials and mechanism